Summit Therapeutics SMMT Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's common stock, shares authorized (in shares)?
- Summit Therapeutics (SMMT) reported common stock, shares authorized (in shares) of $1B in Q1 2026.
- How has Summit Therapeutics's common stock, shares authorized (in shares) changed year-over-year?
- Summit Therapeutics's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $1B to $1B.
- What is the long-term trend for Summit Therapeutics's common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Summit Therapeutics's common stock, shares authorized (in shares) has grown at a 32.0% compound annual growth rate (CAGR), from $250M to $1B.